RESPILIQ - “the liquid breath”

O11 biomedical is focused on developing an innovative oral therapy candidate for respiratory diseases, specifically targeting hypercapnia.

RESPILIQ is designed to use the human intestines as a respiratory organ. The human intestine forms a highly effective CO₂ exchange membrane. RESPILIQ demonstrated CO₂ binding in the gastrointestinal tract in preclinical studies. 

O11 biomedical GmbH is a spin-off from the Aachen University Hospital and the Dept.of Applied Medical Engineering (AME), Institute of Biohybrids & Medical Textiles (BioTex) at RWTH Aachen University.

We unite experts in life science, engineering, clinical development, medical technology, and medical expertise in internal medicine, cardiology and pulmonology as well as in intensive care medicine and cardiothoracic surgery